Although results from the PRIMARY clinical trial showed improved sensitivity and negative predictive value for the detection of clinically significant cancer with PSMA PET compared to MRI [81], it is unclear what added advantage exists for using PSMA PET images alone or in combination with MRI images over MRI alone for focal boosting or even for focal prostate treatments. The gene discussed is FOLH1; the disease is cancer.